nicotinamide/Finding
One finding, on its own
A single claim from the graph, with the evidence strength computed from its study, the sentence it was drawn from, and the paper. This address does not change.
Increases withdrawal due to adverse events
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.Finding“The percentage of patients who permanently discontinued the intake of study medication due to AEs was significantly higher in the NAMR group compared with the placebo group [NAMR: 21.5% (n = 116) versus placebo: 11.5% (n = 21), P =.003].”
Quoted verbatim from Modified-release nicotinamide for the treatment of hyperphosphataemia in haemodialysis patients: 52-week efficacy and safety results of the phase 3 randomized controlled NOPHOS trial.. - Study
- RCT
- Duration
- 12 months
- Dose
- modified-release nicotinamide 250-1500 mg/day (one to six 250 mg capsules once daily before bed)
- Population
- Safety population of adults on maintenance haemodialysis with hyperphosphataemia, modified-release nicotinamide versus placebo, both arms on their individual phosphate binders
Modified-release nicotinamide for the treatment of hyperphosphataemia in haemodialysis patients: 52-week efficacy and safety results of the phase 3 randomized controlled NOPHOS trial.2023PMID:35751625Industry fundedPermalink
Keep reading
- Everything the graph holds on nicotinamide
- Every compound studied against Withdrawal due to adverse events
- How to read the evidence strength and the marks
To cite this finding: https://catalystproject.ai/e/01M4PFZ4ADPQH02YV66GTWBP6A